KRAS and lung cancer: Previous studies revealed that IL-1β is a potent activator of the NF-κB pathway (13, 14), and our group also demonstrated essential roles for NF-κB–mediated production of cytokines in the promotion of K-ras–mutant lung cancer in CC-LR mice (10, 24, 25).